Cerenovus, part of Johnson & Johnson MedTech, has announced the launch of its Cereglide 71 device—a next-generation intermediate catheter with TruCourse technology indicated for the revascularisation of patients suffering from acute ischaemic stroke. The device is now commercially available in the USA.
The Cereglide 71 intermediate catheter is the latest innovation in a planned Cereglide family of catheters to join the Cerenovus Stroke Solutions portfolio, according to a company press release. The device is optimised for effective direct aspiration, and for the delivery of compatible stent retrievers—including the Embotrap III revascularisation device—into the neurovasculature.
Cereglide 71 is equipped with TruCourse technology to increase flexibility of the device, and is designed to help physicians with improved navigation and access to clots—even in challenging anatomical conditions. Cerenovus claims the device is intended to provide physicians with optimal compatibility, durable delivery, and reliable trackability, during thrombectomy procedures.
“In the rapidly evolving landscape of neuroendovascular stroke care, staying on the cutting edge is crucial for advancing the field and ensuring physicians have the tools to navigate complex patient anatomy,” said Fawaz Al-Mufti (Westchester Medical Center/New York Medical College, New York, USA). “Balancing trackability, support and aspiration efficacy is crucial in overcoming the challenges of swift clot access during endovascular thrombectomy. As the global first user, in initial use, Cereglide 71 intermediate catheter does just that. It impressively navigates, accesses occlusion sites, and engages with effectiveness to aspirate clots, rapidly restoring blood flow in the patient’s brain—potentially a life-saving intervention.”
According to the press release, devices within Cerenovus’ Stroke Solutions portfolio are developed using the company’s expert stroke science insights from its Neuro Thromboembolic Initiative (NTI), resulting in products that have been tested in models that recreate real-world scenarios and seek to further address clinical unmet need.
The Cereglide 71 intermediate catheter will also be included in the next phase of the Cerenovus EXCELLENT registry, a real-world registry focused on studying stroke-inducing blood clot removal by mechanical thrombectomy.
“Cereglide 71 intermediate catheter is specifically designed to glide through challenging anatomical conditions,” said Mark Dickinson, worldwide president, Cerenovus. “Developed through robust research and clinical insights, our team designed a catheter for physicians that addresses unmet clinical needs by providing reliable trackability, durable delivery, and the versatility for both direct aspiration and stent-retriever use, even in the most challenging anatomical conditions.”
